Reply: Pulsed Field Ablation for Persistent Atrial Fibrillation: Do Electrophysiological Endpoints Predict Clinical Benefit?

Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F20%3A00008806" target="_blank" >RIV/00023884:_____/20:00008806 - isvavai.cz</a>
Výsledek na webu
<a href="https://pubmed.ncbi.nlm.nih.gov/33334431/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/33334431/</a>
DOI - Digital Object Identifier
—

Jazyk výsledku
angličtina
Název v původním jazyce
Reply: Pulsed Field Ablation for Persistent Atrial Fibrillation: Do Electrophysiological Endpoints Predict Clinical Benefit?
Popis výsledku v původním jazyce
The trial was supported by the manufacturer of the ablation system, Farapulse Inc. Dr. Reddy has stock in Farapulse; and has served as a consultant to Farapulse, Biosense-Webster, and Boston Scientific. Dr. Neuzil has received grant support from Farapulse. Dr. Anic has received grant support from and has served as consultant to Farapulse. John Mandrola, MD, served as Guest Associate Editor for this paper. Deepak L. Bhatt, MD, MPH, served as Guest Editor-in-Chief for this paper.
Název v anglickém jazyce
Reply: Pulsed Field Ablation for Persistent Atrial Fibrillation: Do Electrophysiological Endpoints Predict Clinical Benefit?
Popis výsledku anglicky
The trial was supported by the manufacturer of the ablation system, Farapulse Inc. Dr. Reddy has stock in Farapulse; and has served as a consultant to Farapulse, Biosense-Webster, and Boston Scientific. Dr. Neuzil has received grant support from Farapulse. Dr. Anic has received grant support from and has served as consultant to Farapulse. John Mandrola, MD, served as Guest Associate Editor for this paper. Deepak L. Bhatt, MD, MPH, served as Guest Editor-in-Chief for this paper.

Rok uplatnění
2020
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Podobné výsledky(10)